TELA Bio (TELA) Free Cash Flow Growth (1y) (2019 - 2026)

TELA Bio (TELA) Free Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -1.82%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 226.77%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 0.77%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -51.69%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -109.40%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 363.84%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -31.71%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 133.09%
10 TELA Bio 38.36 Mn -1.18 Mn 12.52 Mn -15.70%

Historic Data

Download Data
DateValue
Mar 31, 2026 -15.70%
Dec 31, 2025 40.55%
Sep 30, 2025 34.86%
Jun 30, 2025 24.18%
Mar 31, 2025 32.99%
Dec 31, 2024 22.47%
Sep 30, 2024 -24.27%
Jun 30, 2024 5.55%
Mar 31, 2024 -24.56%
Dec 31, 2023 -5.90%
Sep 30, 2023 12.05%
Jun 30, 2023 2.59%
Mar 31, 2023 -8.57%
Dec 31, 2022 -5.25%
Sep 30, 2022 -24.69%
Jun 30, 2022 -103.33%
Mar 31, 2022 -25.08%
Dec 31, 2021 -38.39%
Sep 30, 2021 -79.43%
Jun 30, 2021 11.42%